An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and a Comparison to Subcutaneous (SC) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept in the same subjects.
• The subject has provided written informed consent with HIPAA authorization before the initiation of any study-related procedures.
• The subject is at least 18 years of age at the time of consent.
• The subject is HIV positive.
• The subject has a biopsy-confirmed diagnosis of KS and is classified into one of the categories below:
‣ Confirmed cutaneous KS/oral lesions without edema.
⁃ Confirmed cutaneous KS/oral lesions with edema.
⁃ Confirmed cutaneous KS/oral lesions with or without edema and suspected non-cutaneous KS due to clinical symptomology or confirmed non-cutaneous KS lesion(s).